1		FEDERAL	TRADE	COMMISSION
2		I N	D E X	
3	SPEAKERS:	PAGE		
4	MR. ALDERUCCI:	12		
5	RICHARD STALLMAN	17		
6	MARY MUSACCHIA	22		
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				

1	FEDERAL TRADE COMMISSION
2	
3	In the Public Hearing on:)
4	COMPETITION AND INTELLECTUAL)
5	PROPERTY LAW AND POLICY IN)
6	THE KNOWLEDGE-BASED ECONOMY.)
7)
8	
9	APRIL 9, 2002
10	
11	Room 432
12	Federal Trade Commission
13	6th Street and Pennsylvania Ave., NW
14	
15	The above-entitled matter came on for hearing,
16	pursuant to notice, at 9:35 a.m.
17	
18	WORKSHOP CHAIRPERSONS:
19	MICHAEL, BARNETT, FTC
20	MATTHEW BYE, FTC
21	JILL PTACEK, DOJ
22	MAGDALEN GREENLIEF, PTO
23	
24	
25	

1	PANEL ON: "CROSS-INDUSTRY PERSPECTIVES ON PATENTS":			
2				
3	DEAN ALDERUCCI,, Walker Digital			
4	LES HART, Harris Corporation			
5	NANCY J. LINCK, Guliford Pharmaceuticals			
6	MARY U. MUSACCHIA, SAS Institute			
7	RICHARD STALLMAN, Free Software Corporation			
8	TIMOTHY CASEY, Fried, Frank, Harris, Shriver & Jacobson			
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				

1 PROCEEDINGS

12

13

14

15

16

17

18

19

2.0

2.1

22

23

2.4

25

industries.

- MR. BARNETT: If we could go ahead and get started.

 Good morning. My name is Mike Barnett. I'm a staff attorney

 here with the Federal Trade Commission, and I'm joined by
- 5 Matthew Bye, also a staff attorney here at the FTC.

I would like to welcome you to this morning's hearing
on cross industry perspectives on patents. This hearing
represents one of several business related hearings dedicated
to various high-tech industries in the fields of
biotechnology, pharmaceuticals, software, the Internet, as
well as various hardware and semiconductor related

This hearing differs from prior business related hearings in that prior hearings have separately dealt with issues related to particular industry groups, whereas today's hearing combines these industries in an effort to explicitly determine how these industries' intellectual property concerns differ and how they are alike.

Joining me today are my colleagues from various government agencies, and I would like to introduce Jill Ptacek from United States Department of Justice and Magdalen Greenlief at United States Patent and Trademark Office.

Gathered with us are representatives from various companies and the legal community to provide us with their insights and experience in patents, competition and

- innovation within their business or field and hopefully, in
- 2 turn, their industries in general.
- In my opinion, I think this is an impressive group of
- 4 individuals who are distinguished in their fields, and I'm
- 5 anxious to hear their thoughts.
- With that, I think we should begin. We will start by
- 7 briefly introducing each panelist, and following their
- 8 introduction, they will provide a brief explanation of what
- 9 their companies do or their area of expertise, to provide us
- 10 with some perspective toward their relationship in the
- industry.
- 12 Following these introductions some of our
- participants have graciously offered to provide brief
- 14 presentations to introduce us to ideas and issues that they
- find particularly relevant and important to the issues at
- 16 hand, at which point then we will begin the moderated
- discussion portion of the hearing.
- To my far right we have Leslie J. Hart. Les Hart is
- 19 Vice President of Intellectual Property for Harris
- 20 Corporation, an international communication equipment company
- 21 with operating divisions serving a variety of communication
- 22 markets.
- 23 Mr. Hart has spent 25 years with Harris
- 24 Corporation. 20 years were as Vice President, General
- 25 Counsel of the semiconductor sector of the business.

1 Les?

2 MR. HART: Yes. A few words on Harris Corporation.

2

- 1 compiler now supports over 30 different architectures and
- 2 seven programming languages.
- 3 Richard?
- 4 MR. STALLMAN: I am not a lawyer. I'm a software
- developer, at least I was before I became the leader of a
- 6 political and social movement. In our movement, we develop
- free software, free as in freedom, which means that you, the
- 8 user, have the freedom to study what the software does,
- 9 change it to suit your needs, distribute it to other people
- and thus form a community where you are allowed to
- 11 cooperate.
- 12 You don't have to do these things yourself. If
- you're a business, say, you could hire a skilled person to do
- 14 it for you. So, these freedoms are vital and important and
- useful for everyone who uses computers.
- 16 Now, this gives us unfortunate experience with the
- 17 patent system.
- 18 MR. BARNETT: Thanks, Richard.
- 19 Next we have Nancy Linck. Nancy Linck is Senior Vice
- 20 President and General Counsel for Guliford Pharmaceuticals,
- 21 Incorporated, in Baltimore, Maryland. Nancy has been with
- 22 Guliford since late 1998 when she resigned her position as
- 23 Solicitor at the United States Patent and Trademark Office
- 24 where she served as Solicitor for four years. Prior to that she
- 25 was partner with the law firm of Cushman, Darby & Cushman. She

- 1 has also taught at both Georgetown Law Center and George
- 2 Washington School of Law as an adjunct professor.
- 3 Nancy?
- 4 MS. LINCK: Thank you. Guliford Pharmaceuticals is a
- 5 publicly traded proprietary drug company, as you were told,
- 6 in Baltimore. It employs 280 people, approximately. It
- 7 changes every day, and we have more than a hundred U.S.
- 8 patents.
- 9 Guliford at this time has one commercial product
- 10 which is used to treat brain cancer, and we have products to
- 11 treat Parkinson's disease, diabetic neuropathy, and ovarian
- 12 and lung cancer.
- 13 As yet, Guliford is not a profitable company.
- 14 Therefore, we have a burn rate of approximately, I believe
- it's \$60 million a year, so in order to stay afloat, we
- depend very heavily on investment in our technologies and on
- 17 partnering primarily with larger drug companies. Thanks.
- 18 MR. BARNETT: Thanks, Nancy.
- Now to my far left we have Dean Alderucci. Dean
- 20 Alderucci is the Chief Counsel of Intellectual Property for
- 21 Walker Digital Management, a business-solution invention and
- 22 development company. He directs the creation and patenting
- 23 of software products and participates in commercialization
- 24 efforts. He has previous experience as an attorney in an
- intellectual property law firm and is a software engineer.

- 1 to work by groups such as Working Mothers and others.
- 2 MR. BARNETT: Thanks, Mary.
- Finally we have Timothy Casey. Tim Casey is a
- 4 partner from Fried, Frank, Harris, Shriver and Jacobson where
- 5 he's Chairman of the firm's intellectual property and
- 6 technology transactions department.
- 7 Prior to joining Fried, Frank, Mr. Casey was Chief
- 8 Technology Counsel, Senior Vice President and Assistant
- 9 Secretary of WorldCom, Inc., where he headed all legal
- 10 aspects of the worldwide technology, intellectual property
- operations of WorldCom and Express MCI Communication Corps.
- 12 He has also held tenures as Director of Intellectual
- 13 Property at Silicon Graphics, Incorporated, and as Divisional
- 14 Patent Counsel at Apple Computer Corporation.
- 15 Tim?
- 16 MR. CASEY: Thank you. That helps explain a little
- 17 bit as to probably why I'm here in that I've only recently
- 18 gone back into private practice after a long time of being
- 19 in-house in the computer software and telecommunications
- industries, so hopefully I'll bring somewhat of a perspective
- 21 from a number of different industries into this discussion
- today.
- MR. BARNETT: Thanks, Tim.
- 24 We'll now begin with the presentations. Dean, would
- 25 you like to start?

1	MR. ALDERUCCI: Mr. Chairman, members and staff of
2	the Federal Trade Commission and officials of the Department
3	of Justice, Walker Digital, like countless other companies
4	and individual inventors, has experienced difficulties due to
5	inadequate PTO funding.

2.0

2.1

2.4

We have consistently supported an increase in PTO funding because our business depends on a timely and quality examination of patent applications. Unfortunately, inadequate funding hinders both.

Financing for PTO operations has not kept up with increases in patent filings, despite the fact that all of our patent laws, and in fact the very theory behind the patent system, are predicated upon an agency that examines patent applications efficiently, accurately and in a timely manner.

During these hearings, a substantial portion of the testimony has referred, directly or indirectly, to PTO fee diversion, and to the resulting scope of patents issued in the United States. Fee diversion is a real issue. Business is paying for a better PTO and not getting it. Unlike FDA fees, which have reduced examination time frames, PTO fees often go straight into the general treasury.

This may help balance the budget, but we all pay the price when hundreds of millions of dollars in PTO funding fail to be spent for their intended use.

Some testimony has also been critical of the patent

- 1 system and its effect on industry, while other testimony has
- 2 indicated that the patent system is essential to
- 3 competition. Some testimony has been conclusory and
- 4 unsubstantiated, and some has been accompanied by extensive
- 5 references and statistics.
- To quote from Professor Lerner's testimony regarding
- our patent system, "the issues are complex, and sometimes
- 8 difficult to understand. Simplistic claims frequently cloud
- 9 these discussions."
- I propose that much of this testimony may be
- 11 reconciled, whether it comes from critics or proponents, from
- 12 academics, practitioners, industry or organizations.
- Both sides agree that the current administration of
- the patent law is not optimal. The proponents of the U.S.
- patent system have requested that the PTO be adequately funded.
- 16 The critics of the U.S. patent system have denounced the
- 17 consequences of the PTO's shortcomings.
- 18 Specifically, the criticism regarding overly broad
- 19 patents, and the ensuing problems that such patents create,
- is ironically largely a similar condemnation of the
- inadequate resources of the PTO.
- So where does the debate diverge?
- The differences between proponents and critics lie in
- their tacit assumptions regarding the PTO's shortcomings.
- 25 Proponents generally believe that the shortcomings are from

- inadequate funding, and consequently more funding would ameliorate conditions at the PTO.
- On the other hand, the critics tend to assume that
 the state of PTO operations is constant. For the critics,

 past problems in the administration of patent laws serve as
 an excuse to demand changes to those laws, rather than

improve the administration problems.

7

15

16

17

18

19

20

2.1

22

23

2.4

25

To the best of my knowledge, the critics have rarely, if ever, addressed whether their arguments would hold if the PTO operated efficiently. It is interesting that the criticism invariably ignores what would happen if the PTO were properly funded, managed and operated. In my opinion this represents an inexcusable gap in the policy analysis of U.S. innovation and competitiveness.

Take the problem of overly broad patents. To the extent that these may be issued, better resouces, properly applied, would help eliminate the problem. There's no substitute, and far more resources will help that. Critics should also not ignore the fact that legal reviews also operate to deal with failures in the examination process.

I define an efficiently operating PTO as one which would, for the vast majority of patent applications, find the most relevant prior art, render cogent decisions on enablement and definiteness of claims, and issue high quality patents in a timely manner.

I note in passing that a mere increase in funding,
without also requiring substantial operational changes,
rarely results in significant improvement of any
organization. It could be demonstrated that an efficient PTO
would cure the shortcomings denounced by critics. Then the
critics and proponents would presumably agree to realize a

common goal -- implementing this efficient PTO.

2.0

2.4

However, I regret that I have never seen an empirical analysis of the competitive benefits of an efficient PTO, nor any estimates of the cost to implement such a PTO, nor any conclusion regarding whether the cost would outweigh the competitive benefits. I am furthermore unaware of any quantitative research that predicts the reaction of businesses to such a new environment. Regarding this lack of empirical data, Judge Michel of the U.S. Court of Appeals for the Federal Circuit has recently complained that many of those who advocate patent reforms offer no support for their claims that there are significant problems and that fundamental reform is needed.

It is reasonable to assume that as the quality of patents increases and the time to patent issuance decreases, businesses would gradually but inevitably alter their strategic behavior in a variety of ways. For example, not only would business alter the amount of resources devoted to acquiring patents, but they would also tend to devote more

1 MR. STALLMAN: Many people assume that it's sensible 2 to have a patent system in software, and they question only 3 details, such as how many patents, which kinds, how broad and 4 so on.

This is, I believe, because there is an emotional attachment to the idea that a system such as the patent system must be a good thing, but in other areas, we're quite capable of looking at a government program that was designed to achieve a certain goal and questioning whether it does achieve that goal, whether it makes any sense at all.

Now, I am a software developer. I don't have much background in other fields of industry, and I don't have an opinion about whether it's good or bad to have a patent system in fields such as pharmaceuticals or automobile manufacturing. I figure I'll leave the discussion of those questions up to the people who know those fields, but I have worked in the software field for a long time. I was in the software field when there were officially no software patents in the U.S., and I've been in it since, and it's clear to me that

- 1 the ones whose validity might be questionable that cause
- 2 obstructions to software development. Even patents covering
- 3 ideas I would say are brilliant have caused tremendous
- 4 obstruction in progress of software.
- 5 There is mathematical research now. I can't show you
- 6 statistics. I don't spend my time studying what the patent
- 7 system does. I spend my time trying to get software
- 8 developed, but I can tell you where to find mathematical
- 9 research showing how patents can obstruct progress in a field 989

- So even finding a better algorithm, which supposedly
 the patent system is supposed to encourage people to do,
 even if you find one, that may not help at all. And when
 there are patents that cover a whole field such as the patent
- on public key encryption, that can lock up the whole field
- 6 of activity for decades.

10

14

15

16

17

18

19

20

21

22

23

- Now, people have the naive idea if you develop a new product, there will be one patent for it and you will "get the patent" and therefore the patent system will benefit you,
- In some fields maybe it's like that, or more or less like that, but fields vary tremendously in how much they are like that. Software is at the opposite extreme.

the developer, of this innovative product.

- If you look at a word processor, you'll see maybe a hundred features. Well, each of those features is something that might, in principle, have been patented by somebody else. It might be patented by someone else. A combination of two features might be patented by someone.
 - And the result is if you want to develop a word processor, even if it has some innovative improvements, you're at tremendous risk of running into patents belonging to others that may make it impossible for you to develop the program.
- 24 Standards that you want to comply with may be covered 25 by patents. Even official standards may be covered by patents,

- which may not matter much in other areas of industry where
- 2 products are made by factories and where you could buy a widget
- 3 that implements a certain standard whose manufacturer licensed
- 4 the patent, and all you have to do is use it.
- 5 It's not like that in software. These licenses are
- 6 referred to as reasonable and nondiscriminatory, both are
- 7 false. They discriminate against free software that we
- 8 develop, and I think that's not reasonable. Many other

- well known British telecom connecting to the machine through a
- telephone line and traversing hyperlink patent.

12

13

14

15

16

17

18

19

2.0

2.1

22

23

2.4

25

- 3 MR. BARNETT: Thank you. Finally, we're going to hear 4 from Mary Musacchia.
- MS. MUSACCHIA: Thank you. On behalf of SAS, I

 commend the Federal Trade Commission and the Department of

 Justice for seeking the views of the business community

 through these hearings and welcome the opportunity to appear

 today to present our perspective. My comments will focus

 exclusively on the controversy surrounding business method

 patents, or BMPs as they're commonly called.

SAS is concerned that the public perception of the patent system has suffered with the introduction and rapid growth of the filing and granting of business method patents. Whether it is a patent on a Dutch auction, a one-click shopping experience, or techniques to pictorially train "cleaners of facilities," the public eye has been turned in the direction, and the question asked, what is the value of a patent system that grants monopolies on such innovations?

The historical justification of patents, as set forth in the Constitution, empowers Congress to create a system to promote the progress of science and useful arts by securing for a limited time to the inventors exclusive rights to their respective discoveries.

In exchange, the inventor makes full disclosure of

1 the invention. The economic theory of patents is that the

disclosure of the innovation will stimulate competition and

further innovations. By virtue of disclosure, society is

4 invited to invent design-arounds and further technological

advances are made, augmenting the storehouse of human

6 knowledge.

plausible payback mechanism.

5

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

2.1

22

23

2.4

25

In industries such as manufacturing and electronics, history proves that this is so. For every new microchip or carburetor, the disclosure of the new invention spurs competition to design improvements. It is also recognized that in some industries, such as pharmaceuticals, a financial recovery incentive may be required because of the expense associated with the original discovery. Society's value to granting this limited monopoly thus must be based upon either a disclosure that would encourage subsequent innovations or encourage expenditures for discoveries by creating a

It has been in the last several years that the scope of patent protection has been enlarged, resulting in a dramatic increase in the number of patents, both filed and issued. Certainly, not an insignificant portion of that growth can be attributed to BMPs that have emerged from the use of the Internet by businesses. These hearings are valuable because they will seek to look at the impact of this change on the economy and as a matter of public policy.

1	Many business method patents simply take a commercial
2	brick and mortar business process and articulate it as an
3	Internet or electronic application. Having minimal or no
4	physical component, business method techniques cross the line
5	into abstractions, mere shadows of innovation. And while
б	mechanical processes have been patented, BMPs are not in
7	keeping with the historical and publicly held belief that
8	patents have an innovative technical character.

2.4

For example, when an electronic device is patented, the disclosure of the new circuit in the text of the patent is expected. With a business method, since the business is already active in the marketplace, there's no incentive to the filer to disclose within the patent.

In many instances, the business process, by its very nature, is already public. Most typically, the underlying technology that is used in the process, the actual lines of code, is not part of the patent filing. What is seen most often is a broad, non-illuminating description of already public techniques. Thus, without information on the technical mechanism, the disclosure of a business method patent fails to augment public knowledge. In effect, there is no longer a quid pro quo, the creation of intellectual property right and its protection in exchange for public disclosure.

In the marketplace, business methods are developed

- 1 not in a research laboratory in a series of sequential
- 2 improvements upon past technology, as in the manufacturing
- and electronics, nor in repeated breakthroughs, as in the
- 4 pharmaceutical industries, but in an arena of competition.
- 5 Iterative emulation, such as Internet advertising and
- 6 commerce, transferring brick and mortar techniques to the
- 7 Internet or systematizing human processes and human
- 8 transactions, appears to be the focus of business method
- 9 changes.

the first-mover advantage is a strong incentive, in many
cases ensuring adequate returns to compensate for the cost of
the implementation of the process. The government does not

need to intervene where the market works.

4

We live in a world that is growing increasingly
smaller. It's been the practice of the USPTO to work with

its counterparts in both Japan and Europe to harmonize the

patent laws. We agree that harmonization is necessary, but

as harmonization would apply to BMPs, the United States should

13 h TD50ncenati6theEPO eval43.5d moniposij -43.n software38.25 50n

recognize business method patents, stating, "Our key principle is that patents should be for technological innovations."

3 The JPO requires that an invention be industrially 4 applicable, and further limited by the requirement that 5 inventions liable to contravene public order, morality or 6 public health shall not be patented. These two requirements 7 have resulted in the JPO refusing to grant patents for new medical treatments, methods of typhoon control and business 8 methods. According to the Japanese, the systemization of 9 10 existing human transactions would not be deemed patentable because it would be obvious to a person in the ordinary skill 11 12 in the art.

13

14

15

16

17

18

19

20

2.1

22

23

2.4

25

The industrial application requirement in both the EPO and JPO, along with their requirement that patentable inventions have a technical character, limits the extent of patent protection that may be received for inventions of an economic nature, a BMP. By explicitly including industrial application as a prerequisite to even entering the realm of patentability, the possibility of protecting processes solely involving economic or personal utility, such as a method of the training of a janitorial staff or the swinging a golf club, is significantly reduced.

In a global marketplace, business method patents may also introduce an artificial constraint on the competitive process and should be evaluated for possible impact to the

- 1 U.S. Economy. Query: If the JPO and the EPO continue their
- 2 restricted approach to recognizing BMPs, will patent seekers
- 3 flock to the United States to obtain a protected monopoly,
- 4 constraining behaviors in the U.S., while leaving the rest of
- 5 the global marketplace free of impediments?
- The dynamics are probably too new to really know how
- 7 this will play out, but it's certainly worth consideration and
- 8 study. If history provides a basis for judgment, there's
- 9 little to suggest that the previous lack of monopoly protection
- 10 for business methods, on any significant scale, hurt the growth
- of U.S. business from the time our Founding Fathers authorized
- 12 Congress to create the patent system over two centuries ago.
- 13 Throughout the course of these hearings, numerous
- 14 suggestions have been made as regards BMPs. SAS has been a
- proponent of full funding for the USPTO. This will help
- improve the quality of the work, benefit those that use the
- 17 system and cease to be an indirect tax on inventors who have
- 18 contributed the most to the U.S. economy over the last two
- 19 years. However, full funding should not be considered a cure
- 20 to a fundamental flaw that exists by granting patents for
- 21 business methods.
- It has been suggested that reducing the life of the
- 23 patents for BMPs to three years would be desirable. While
- this would be an improvement on where we stand today, it
- again does not address the underlying public policy issue.

- 1 If BMPs have been defined clearly enough, they can be defined
- 2 clearly enough not to be granted.
- Whatever action may be considered, it should be
- 4 conducive to harmonization on a global basis. There are no
- 5 borders, and careful consideration should be given to moving
- 6 towards the positions of the EPO and the JPO on this
- 7 subject.
- 8 I thank you for affording SAS the opportunity to
- 9 participate.
- MR. BARNETT: Thank you, Mary.
- 11 With these ideas in mind, I would like to begin the
- discussion portion of the hearing. Let me start with just,
- more or less, some rules of the game. If during the course of
- 14 discussion during the panel, you would like to contribute,
- just take your nameplate and stand it on end like this,
- and that way we can call on everybody in turn, and nobody has
- to waive their arms or anything along those lines.
- I think at that point then we should start. I might
- 19 go ahead and start by asking either Les or Nancy or Tim if
- they have any comments based upon what they've heard from the
- 21 various presentations? Since they elected not to give a
- 22 presentation in this case, if they had any particular
- comments based on what's been said?
- Sure, go ahead, Nancy.
- MS. LINCK: I do have one general comment. There's

1 been a lot of discussion about improving the quality of

31

difficult situation if they try to go to the office and get a

- patent reexamined. There's pending legislation -- HR 1856,
- 3 1886, and Senate Bill 1754 -- that would go a long way to fixing
- 4 the reexamination system we have now. That way we could
- 5 focus funds on fixing bad patents that get through the
- 6 system -- and they do get through, it's inevitable -- rather
- 7 than focusing so much on trying to make every single patent that
- 8 the office examines a high quality patent. I just think it's
- 9 not really possible. We could hope for it, but I just don't
- 10 think it's possible.
- 11 MR. BARNETT: Thanks, Nancy. I think Tim had a
- 12 comment and then Les.
- MR. CASEY: Yes. First, I have to clarify that I'm
- not here speaking on behalf of anybody. This is just on my own,
- so my views don't represent any views of a particular client or
- 16 that necessarily of the firm, just of myself.
- I would like to address a couple things that came up
- 18 as a result of the prepared presentations, and that
- 19 is Mary's comment about the disclosure function of
- the patent system. It is a good one, but in many ways, in
- 21 response to Richard's comments regarding software
- 22 patents, if you had an example where development was being
- done on a data compression technology, and you had a
- 24 disclosure of that patent, then a lot of time wouldn't have
- been wasted developing it, possibly because you would have

- development of the current patent system in which states
- 2 issued their own patents, and look at some of the disputes
- 3 that arose as a result of the fact that we didn't have a
- federalized system. And so you had a lot of disputes between
- 5 different states issuing different patents to people on roughly
- 6 the same inventions. There's a big story about steamboats and
- 7 patents being issued on different steamboat designs.
- 8 And in part, the federal system rationalized that,
- 9 taking common law perspective and putting it into a
- 10 common scheme that was utilized across the board. And that
- 11 had some fairly significant benefits, but even back then
- people complained about patents. They complained they weren't
- being adequately examined, and in fact for a period of time they
- weren't examined at all. They complained they were inhibiting
- the industry, yet we seemed to have developed anyway.
- In fact, ten years ago I was in a panel with Richard
- 17 where the PTO was having a number of hearings about software
- 18 patents. One of the panels was in San Jose, and his
- 19 argument at the time was roughly the same as it is now, that
- 20 software patents are going to destroy the software industry.
- 21 But other than a few isolated examples where patents were
- issued on stuff that perhaps they shouldn't have been issued
- on, it's hard to see how the software industry has been
- destroyed.
- So you leave some question as to whether or not the

- 1 Microsoft is one of these companies that it has been able to
- license this technology out to, or would they have never been
- 3 in the sort of economic position they were in at the time
- 4 that they entered the license had they never had to pay for
- 5 licenses from other people in the first place and spent money
- on a patent development program? It's impossible to say.
- 7 But what you can do is you can look at the data
- 8 that's there. You can look at when these announcements were
- 9 made, and you can track the progress from those particular
- 10 dates, and there is at least some evidence that there was a
- 11 benefit to it.
- 12 MR. BARNETT: Les, do you want to comment?
- 13 MR. HART: I would like to comment on all the patents
- coming out of the patent office. At one end of the spectrum,
- to litigate a patent day, it's fairly complex. You're
- 16 talking \$2 million in legal fees, so at the far end of the
- spectrum, you would think, "Well, it's very dangerous and very
- 18 expensive to have obviously invalid patents out there."
- 19 But let me suggest that from my experience where I
- 20 have licensed semiconductor patents for 20 years, both
- licensing mine and being the object of infringement claims by
- others, that reasonable business people negotiating patent
- 23 licenses are not going to run the risk of getting involved in
- 24 a \$2 million per patent litigation.
- 25 If a patent was being asserted against me or I'm

asserting it against someone else and someone comes up with prior art, clearly if it anticipates those claims, the basis of one or two reasonable people withdraw those patents from consideration. They're dead. They know it, and no one is

2.0

2.1

2.4

So there is a screening process that exists in the real world that I have experienced that says, sure, some patents are going to slip by. I've seen it where it appears to be an immature examiner who just missed some classes that he should have searched in, but in my experience that hasn't happened very often.

going to risk a \$2 million per patent litigation over that.

MR. BARNETT: Thanks. Richard, you had a comment?

MR. STALLMAN: Yes. I feel that you have

misrepresented what I said both in San Jose ten years ago and what I said today. First of all, you've been very convincing in arguing that owning patents has been beneficial for the companies you've worked for. I'm not surprised. I wouldn't argue against that, but you gave me some advice in a rather condescending way. In order to give someone advice, you really should study the scenario first.

This program I was talking about was written about a year after someone saw an article in a journal, so even with today's practice of sometimes publishing patent applications after 18 months, he still would have been blindsided, and the later program that was destroyed, well, it wouldn't have

- those companies as well?
- MR. CASEY: Most of the time that's the way they work
- 3 out, absent cross licenses.
- 4 MR. STALLMAN: Right. What this shows is your patent
- 5 didn't even protect you from the big companies that might
- 6 have wanted to compete with you.
- 7 MR. CASEY: That's because there weren't very many at
- 8 the time. You cross licensed, but you didn't cross license
- 9 very much. That gave you an impetus to develop more, so you
- 10 weren't quite so one sided.
- 11 MR. STALLMAN: I'm sure it gives an impetus.
- 12 MR. BARNETT: We might step back for a moment, and
- one thing that we're interested in, I think, is the role that
- 14 patents play in a company's innovation decisions. In other
- words, why are companies innovating and where does the
- decision to patent fit in with all this?
- I might open this up to the panel. That question is,
- 18 intuitively patents are arguably spurring innovation, but where
- does it fit in with the company's framework or the inventor's
- 20 framework? Does anyone have any
- 21 thoughts? Dean?
- 22 MR. ALDERUCCI: I would like to note that the
- 23 innovation spurred by the patent system is really two
- 24 components. One is the incentives that flow from
- 25 protecting your intellectual property, but the other, which is

- 1 rarely talked about, I found is the ability of anyone to
- 2 review the public disclosures in issued patents or published
- 3 patent applications.
- And to the extent that it's a patent and it's
- 5 expired, you're free to use anything that is claimed or

- 1 title of the abstract, might not deal with that technology
- 2 area.
- For example, I remember a patent that dealt with a
- 4 vending machine. It was basically a very simple vending
- 5 machine. In the middle of the patent, seemingly out of
- 6 place, was a very helpful description of revenue management
- 7 technique. If anyone who knows what revenue management
- 8 technique is, it's basically a way to alter your prices so you
- 9 can optimize your profits.
- 10 It really wasn't expected in the middle of a patent
- 11 regarding a vending machine which allowed the user to reach
- in and take the food product themselves, which was part of the
- innovation. But my point is, when you look at the disclosure
- that the public patent system provides and you take advantage
- of that disclosure, then you're much better off, and it tends
- 16 to increase your ability to innovate.
- 17 MR. BARNETT: Les, did you have a comment?
- 18 MR. HART: I'll use Harris Corporation as an example
- 19 of innovation and the part that it plays in management of the
- 20 company. Harris got in to the semiconductor business in the
- 21 early '60s, like many other companies like Intel and many
- others, and once you started having sales, the first patented
- company that would approach you would be Western Electric,
- 24 AT&T, Bell Laboratories, because they had the patent on the
- 25 transistor.

1	That started the process at Harris of, say, you
2	went from the point where you had no patents and you were
3	building infringing product. You went from there, you
4	migrated from there to the point of saying, "We better get
5	some patents because the next time we have to deal with
6	Western Electric five years from now we better have some
7	patents that hopefully are infringed by Western Electric."

2.0

2.1

2.4

From that point you migrate even further, and if you're really in a hurry to get patents, you might even consider buying them from other companies, and that's happening with an increasing frequency today, not so much 25 or 30 years ago. But in the migration path of innovation, you're at the point now where you get patents for defensive purposes, to defend yourself from somebody else with more patents who comes after you.

Time marches on, and in the migration of the importance of innovation, most of these companies in the semiconductor industry are spending 12 to 15 percent annually of their sales on R&D. You finally get to the point in the migration of this where instead of being defensive, your accumulation of patents may put you in a position that you can license them actively and get a return, monetary return, so that you can use that money to make further R&D investments.

It migrates even further, and I think there are parts

- 1 MS. MUSACCHIA: The question that you proposed was,
- 2 "How do your companies look at patents or innovation, how does
- 3 it impact your planning?" and for SAS it does not, and it

obviously can't file a patent on something until it's been

1	We represent a lot of investors. They're making
2	investments in pharmaceutical companies, and in doing due
3	diligence and trying to help those investors analyze what it
4	is they're getting into, most of the time the investment
5	decision rests upon how strong a patent protection that they've
6	been able to develop or the potential for that patent
7	protection based on pending applications that the company's
8	been able to develop, and that alone is a primary determinant
9	valuation in what kind of investment they're going to make.
10	So if you throw that away, you throw the patent
11	system away. In that particular industry, and that industry

- was Deutsche increased its price to a point where General
- 2 decided it was worth doing the deal after all. They went ahead
- 3 with the merger, and there went the patent litigation.
- 4 So the patent litigation in that instance was a tool
- 5 that ended up being used more by General than Deutsche because
- 6 Deutsche filed it, because it gave them an opportunity to help
- 7 to increase the price the shareholders were getting for the
- 8 company.
- 9 Does that really have anything to do with patents?
- Not necessarily, it's just another tool in industry
- 11 manipulation in corporate development.
- MR. BARNETT: Nancy, I was wanting to hear your
- 13 comments on that, coming from the pharmaceutical industry as
- well as PTO, but what are your thoughts in particular in
- 15 addition to any others, on the notion that different
- 16 industries are different from a patent perspective?
- 17 MS. LINCK: I think they are different, but maybe more
- in their stage of evolution. I mean, Tim is absolutely right.
- 19 For proprietary drug companies and even for generics, patents
- are absolutely critical. We do not move forward for
- developing a drug for which we don't have patent protection,
- 22 that is a given. We can't bring in investor funds.
- 23 As I explained earlier, that's critical to our
- 24 company right now. Unless we have a big patent estate, a
- strong patent stake, we can't patent with big pharma unless

- 1 we have a strong patent stake.
- When I was the solicitor, I worked actually on the
- 3 software guidelines, and we did a lot of research on whether
- 4 or not software should be patentable, and initially we took
- 5 the position that it shouldn't be. We wanted to take the
- 6 <u>In Re Lowrey</u> case up to the Supreme Court and see if we could
- 7 get the Supreme Court to reverse the Federal Circuit.
- 8 And it was actually someone in the antitrust division
- 9 of the Department of Justice that convinced me that software
- should be patentable, but if antitrust thinks software should
- 11 be patentable and the PTO thinks it shouldn't be, there's
- 12 something wrong with this picture.
- Going back to the importance to different
- industries, I think it's absolutely clear today, but when we
- were looking into whether or not we should patent software,
- 16 the hope was that while the software industry was making
- 17 little tiny steps advancing its art, perhaps by providing more
- meaningful protection through patents rather than copyrights we
- 19 would see more significant inventions being made in the
- 20 industry.
- 21 And, frankly, once we started patenting software, I
- 22 haven't studied that issue, and I don't know whether that has
- 23 happened, but certainly that was one of our rationale for
- 24 moving forward.
- I think also those who work in the intellectual

- 1 property area, patents specifically, for the most part
- 2 believe strongly that different technology should not be
- 3 treated differently. They have not been treated differently
- 4 for several hundred years and our system continues to work
- 5 very well.
- 6 And while there have been times when there have been
- 7 questions about patenting different technologies such as
- 8 life, the <u>Chakrabarty</u> case, we've moved forward with saying that
- 9 inventions in that field should be patentable. I think before
- 10 we change that, before we treat different technologies
- differently, we should really move very slowly to make sure that
- that's not going to negatively impact the way our system works.
- MR. BARNETT: Richard?
- 14 MR. STALLMAN: What we've seen here is a
- 15 recommendation that there's no need for caution before you
- 16 impose the patent system on a field that hasn't had it
- 17 before, but there is a recommendation for caution in not
- 18 making that change.
- 19 Why in the world should all fields be treated alike?
- 20 It seems like sort of a religious assumption when you can easily
- see that the relationship between patents and products is very
- different between different fields, and that means the effect of
- 23 having patents is very different in different fields. Never
- 24 will the software field evolve to be like pharmaceuticals.
- What it takes to develop a pharmaceutical, to find a

51

1 pharmaceutical that will work and then to test it is very,

- very different from what's involved in developing a program.
- 3 Many drugs are polypeptides. They are proteins, essentially.
- 4 Do you know how many amino acids typically appear in a large
- 5 protein drawing or how many atoms would appear in a drug that is
- 6 not a protein, an order of magnitude even?
- 7 I would guess thousands of amino acids or maybe
- 8 thousands of atoms in something that is not a protein is the
- 9 limit of what humans can do. Now, this is because that field
- 10 is terribly hard. I'm not saying that those people are not
- 11 smart. I'm saying that the field, what they have to do, is so
- 12 hard.
- For us, what we have to do is much easier, so a
- 14 program with a thousand components in it, a thousand
- operators, that's trivial and you can write that in a week.
- 16 Hard programs have maybe millions of operators in them. You
- might have 20 operators to choose from, just as there's 20
- 18 amino acids you could choose from in a protein. So what this
- 19 shows is how different the jobs are that we have to do.
- 20 And then you get these fairly simple designs that are
- 21 terribly hard to develop and test, and then you get a patent
- on the whole thing. In software, if a patent covered a
- 23 single entire program, it wouldn't cause any trouble, so
- 24 patents affect and relate to products very differently
- 25 in these two fields. I think these are the obvious candidates

- for being treated differently.
- 2 MR. BARNETT: I might ask Dean and Mary, because
- 3 they're both in software related fields, what their thoughts
- 4 are, and then we might go to a break after that.
- 5 MR. ALDERUCCI: I would like to clarify that software
- is provided for the more commonly assumed software that is
- developed for PCs or services. There's also invented software.
- 8 There's software that goes into very low tech devices, and I'll
- 9 give one specific example.
- 10 Software is now used in cash registers. The industry
- likes to call them point of sale terminals, but most people
- would probably call them cash registers. By development, I mean
- the ability to replicate a process that has been demonstrated to
- work on, for example, a cash register might be very simple. It
- might be the case that once a given piece of software is proven
- 16 to work very well in an environment, in a business environment,
- 17 then it might be a very good business decision to copy it.
- 18 Now, it might also be true that even though this
- 19 software was very simple to develop, it was very difficult to
- 20 prove that it would work. Now, what I mean by work is that
- it would actually have a net benefit to the business, that it
- 22 would, for example, increase the sales of whatever business
- is running the software.
- So you can see in a certain type of industry that
- 25 wouldn't be very open to innovation -- let's say it's an

- industry in a subsegment of retail that's not very
- open to innovation -- if you had to convince this business
- 3 that it was going to interact differently with its customers in
- 4 order to increase a profit, the natural reaction is going to be
- 5 reluctance.
- 6 You might have to expend significant resources in

- in the testing. The development is in the prototyping on
- 2 various industries, collecting the statistics, tweaking what
- 3 works and doesn't work.
- And I'll note along these same lines, Mary made a
- 5 comment that business methods are not developed in a
- 6 sequential testing and research manner, and that's just
- 7 completely untrue, at least in the business segments that
- 8 I've been involved in.
- 9 MR. BARNETT: Mary, I'm curious on your thoughts,
- 10 particularly from the standpoint of your comments earlier
- about SAS's approach to patenting, but also just in general.
- 12 MS. MUSACCHIA: I think that what I've tried to do is
- articulate, in the business method arena what you begin to
- see is really an effort by businesses to take events that are
- already known in most cases, process that for the most part.
- 16 I think it's a phrase out of the Japanese phrase, it's the
- 17 human transaction that already exists, and you now

- that I'm trying to direct it to.
- In terms of the laboratory reference, the suggestion
- 3 there is that again in most places people have studied the
- 4 marketplace in a lot of these business methods that I'm
- 5 discussing, and they just look at what exists out there.
- 6 They see what is happening, whether it's in the financial
- 7 industry, whether it's in the food service industry,
- 8 whatever, in the janitorial industry.
- I still struggle with that one every time I've read
- that patent, claims and all, and I sit there and say, "Oh, I
 - 8Warkeliein t TDn-24 nly doDn-24add638.innovaatorof thys and you'v

- that feel you can do this and they are doing it right now, so
- 2 that is again where we come back and say, "Take a look at what
- is going on in Europe and Japan and other places,
- 4 particularly as it relates to this category of patents and
- 5 let's move in that direction." That's our fundamental
- 6 position. That's where we believe it needs to go.
- 7 Finally, just one other point, an intellectual
- 8 property right such as patent isn't like the right to
- 9 breathe. It isn't like the right to live. It is something
- 10 that is created by man in the Constitution. So when we talk
- about protecting it, that is something again where we're talking
- about protecting the original concept that was created by all of
- us that sits in our Constitution, and we have evolved.
- 14 Congress evolved it. The Courts have evolved it.
- 15 There is nothing wrong with going back and taking a look and
- 16 saying, "Was the original purpose still being served?" and I'm
- 17 not a constitutional scholar, don't hold myself out to be
- one, but I certainly think it is again an issue that was
- 19 debated at the time. It's debated now, and we don't believe
- that we really are adhering to some of the original precepts
- 21 which is the quid pro quo for society.
- What do we get? Do we really spur innovation? Is it
- something we need to protect?
- 24 MR. BARNETT: Just as a quick follow-up, would you
- 25 have the same thoughts with software patents that are

- 1 arguably not business method patents?
- 2 MS. MUSACCHIA: Some patents that are not business
- 3 method patents, SAS would take the position that we also, had
- 4 we had our druthers, we would not have software patents.
- 5 That is water that has gone so far under the bridge of over
- 6 the past more than two decades. That is a discussion that we
- 7 think, while we would have loved for it to have happened and
- 8 for there never to have been software patents, we think
- 9 that's probably something that cannot be reversed, whereas
- 10 business methods is one that is so new the die is not so
- irretrievably cast that it cannot be pulled back, and that's
- why our comments are very heavily focused on the business
- 13 method arena.
- MR. BARNETT: We might go with Dean, Richard and then
- 15 Tim.
- 16 MR. ALDERUCCI: I'll be very quick. I just want to
- 17 say, Mary, a large part of what you just said was basically
- 18 business systems that already exist in the public knowledge
- 19 should not be patented. I agree 100 percent.
- I know for a fact that's why there's a Section 102
- 21 and Section 103 in the patent statute, but I also note that
- the division or the way to categorize a business method is
- 23 not well defined. As far as I know I've never seen a
- 24 definition put forth that basically says a business method
- invention is one which is a copy of something being done in

- existence, but now it is in electronic form. That is clearly
- 2 not patentable, and there's clearly a remedy.
- I'll just mention in passing, and I'll go to Richard
- 4 who has been waiting patiently, we, through our subsidiaries
- 5 and joint venture partners, have been on the receiving end of
- 6 overly broad patents. People have asserted certain patents
- 7 cover certain operations that we were performing or
- 8 contemplating performing, and it was a fairly straightforward
- 9 exercise for our research department to investigate the
- 10 relevant prior art and therefore obviate any further
- 11 discussion on the matter.
- Now, it does take a bit of research, and our average
- is around -- last time we did an average was several months
- 14 ago -- 26 hours of priority search per patent, when you want
- to be completely sure you're not going to infringe someone's
- 16 patent. For example, when you're presented with someone
- 17 else's patent, you do a little bit more, but really in the
- 18 scheme of things it's not that much to invest.
- 19 MS. MUSACCHIA: Richard, if you'll let me add one
- thing before we move on to you. Again this is why we have
- 21 pushed so hard that we look over at, for example, what's
- 22 going on in Europe because -- nobody has had a
- 23 monopoly on brilliance, and I think all of us would agree --
- 24 Europe at least has three tests they look at regarding your
- 25 patent. That invention, it has to have a technical field. You

- 1 have to solve a technical problem, get into a technical field,
- 2 enough to have technical features.
- 3 They do have criteria that they look at that help you
- 4 get to the definition of what can be a business method
- 5 patent, something that they can use to help articulate that.
- 6 So again it's why we continually urge because we believe in a
- 7 world without borders. For all practical purposes, in most
- 8 business, harmonization is important.
- 9 Look at what they're doing in Europe. Look at those
- 10 combinations of criteria that they use, and then implement
- 11 that, take some of that and put it together. You can do
- the same thing in Japan, and at that point you have the three
- largest patenting bodies together: EPO, JPO, and USPTO, and
- that's where we all need to move.
- 15 And why force in these harmonization discussions --
- 16 why send our U.S. patent office representative over there and
- 17 constantly tell them to move in the direction, move in that
- 18 direction, come to the U.S. Why not for once throw them a
- 19 carrot and go in their direction?
- MR. BARNETT: Richard?
- MR. STALLMAN: Many distinctions are made by lawyers
- 22 which are not presented to you clear-cut. For instance,
- there's a law against driving while intoxicated by alcohol.
- 24 There's no place you can draw the line between drunk and
- sober. In fact, there's a continuum stretching from cold

- sober to drunken unconscious, and there is absolutely no
- 2 place to draw a line that's any better than any other, so an
- 3 arbitrary line was drawn.
- 4 It's better than treating the two of them alike.
- 5 This idea that makes it seem hard is something that people do
- 6 when they don't want the job to be done. They try to
- 7 discourage from trying by making it seem impossibly hard.
- Now, Dean -- is it? -- presented us with one scenario
- 9 full of maybes: maybe this might happen, maybe that will
- 10 happen, and the result might be an innovation in, say, point of
- 11 sale terminals.
- 12 Well, I'm not sure we should pay much attention to a
- scenario with so many maybes on it, but supposing it did
- happen, the biggest part of their work would have been in
- establishing relationships with customers.
- 16 So this company which had invested so much effort in
- 17 establishing these relationships would get a very direct
- 18 benefit from doing so. They had an idea which probably took
- 19 a second, wrote a program which might have taken a few weeks
- or maybe even a few months, and then spent a lot of resources
- 21 developing these relationships.
- 22 Well, then why shouldn't I be able to spend an equal
- few weeks or few months and then try myself to develop such
- relationships with some customers?
- Now, there are two possibilities here. Either I'm a

- big established company, and I've got a lot of patents that I
- 2 made them cross license me anyway, in which case their patent
- is not going to do any good against me, or I'm so newcomer
- 4 and I haven't got a ghost of a chance of selling to those
- 5 companies unless I've got some other big advantage.
- 6 Why should the government create a secondary monopoly
- 7 for them to pile on to their relationship that they built with
- 8 these customers?
- Anyway, this scenario may be a possible one.
- 10 It could be one way in which society could develop and put
- into use such improvements in point of sale terminals, but
- 12 there's another way it can happen. Somebody who makes point
- of sale terminals could put in the feature they think is
- better and put that in their competition with other companies
- that make such terminals, and then another company can see
- that and say, "Well, gee I don't think that's guite so good, I
- 17 think I can do it better, " and they could tweak it
- 18 differently.
- Just because you can show a scenario whereby with a
- 20 patent system companies could take advantage of that, that
- doesn't mean society needs it to create monopolies in order
- 22 to get these things done at all. There are other ways that
- things like that have happened in the past and can still
- happen today.
- MR. BARNETT: Tim and then Dean, and then we'll take

- 1 the protection on those interfaces is going to be the
- 2 simplest. That is then, the more valuable it's going to be
- 3 because it's going to be utilized by other people.
- 4 You have to have some levels of complexity, but where
- 5 the real value comes in is where you create a simple
- 6 interface between the human whose attempting to interact with
- 7 the technology and the technology itself.
- 8 The other thing that I wanted to touch on is I don't
- 9 think it's so easy to define what exactly is technology.
- 10 What is a technical field? Where exactly did you have a
- 11 technical problem?
- 12 I'm an electrical engineer by original training and
- 13 practice. I look at a lot of patented inventions or things
- people are interested in protecting, and I think it's very
- difficult to be able to define exactly where the technology
- stops and something else starts.
- 17 It's perhaps like Richard's example of when you're
- drunk or when you're sober. Although I think there was some
- 19 empirical data of when you were impaired or not impaired. They
- 20 did test that a little bit, although maybe they made it
- 21 up. I don't know.
- But I think drawing that line between where does
- 23 technology start and stop is also very similar. We would
- have to do it on a guess, and whether or not that
- 25 guess is correct is hard to say.

1 MR. E	BARNETT: Dean,	, and then	we'll	take a	break.
---------	----------------	------------	-------	--------	--------

- MR. ALDERUCCI: I'll briefly comment. Mary has an
- 3 excellent suggestion regarding harmonization between the
- 4 Europe and Japan, and I'm a big proponent of harmonization
- 5 for other reasons, but I would note that there are several
- 6 recent court decisions in New York regarding what the
- 7 technical effect is.
- 8 There's an excellent book by an associate of mine
- 9 named number Keith Ferrisberg who is a European patent
- 10 attorney. He's written a book of software patents in
- 11 Europe, and he has several examples of that -- and if you'll
- call him up, he'll be glad to give you more -- but there are
- 13 several examples of what a technical effect is and there are
- 14 a few recent ones that say a sufficient technical effect is,
- for example, to increase user friendliness to increase profit
- and sales. So I think the Europeans are actually divergent to
- more of a U.S. viewpoint.

MR. BARNETT: I'm sorry, I thought you we ou 8y divergent to

- 1 I think I would like to hear your thoughts on reexamination
- versus litigation and why reexamination isn't used more.
- 3 MS. LINCK: Thank you. Obviously for a small company
- 4 like mine, litigation is really not an option, so that's one
- 5 reason why I'm stressing the importance of a strong
- 6 reexamination system.
- 7 The system that presently is in place, at least the
- 8 inter partes system, began as legislation back in 1990 or so
- 9 that would have, in fact, provided us with a system that would
- 10 have been useful to address bad patents rather than
- 11 litigate.
- 12 It provided for a right of appeal to the Federal
- 13 Circuit for patent challengers or third parties, and it also
- did not have the estoppel provision that ultimately ended up
- in the legislation that now kicks in the minute that a
- third-party files a reexamination. That third-party cannot
- 17 later raise issues that either were raised or could have been
- raised during reexamination later in litigation if that party is
- 19 sued. That patent, of course, if it makes it through reexam,
- 20 it's not strengthened legally, but in fact, in the eyes of the
- 21 jury or the eyes of the Court, if it's been through the process
- twice, it's considered to be a stronger patent.
- 23 So once a third-party goes into reexam, they need the
- right to be able to take that reexam all the way up to the
- 25 Federal Circuit and out of the Patent and Trademark Office,

- and they need the ability to be able to raise issues later on
- in a court action, if they don't ever get into Federal Court.
- I think it's fair that once a third-party takes a reexam into
- 4 Federal Court, then they should be estopped from raising
- 5 issues that they raised or could have raised.
- 6 Right now, there is legislation pending, as I
- 7 mentioned, that would provide third parties with the right to
- 8 appeal to the Federal Circuit. The estoppel provisions that
- 9 kick in the minute reexam is filed would not be corrected by
- the pending legislation, and I would urge the FTC and DOJ to
- 11 support the pending legislation that would fix reexam, but
- also to urge Congress to fix the estoppel provision.
- There's also another problem with the reexam as it is
- today. When I was a solicitor, a case came down, <u>In Re Portola</u>
- 15 <u>Packaging</u>, where the court said that any patent that
- 16 was before the patent office as prior art during the first
- 17 examination could not be relied upon during reexamination,
- 18 that there was a presumption that, in fact, the office did its
- 19 job and considered every single piece of prior art, not only
- alone, but in combination with every other piece of prior art
- 21 that had been cited during original reexamination, and that
- is just not realistic. The office is very limited on its
- 23 time to examine patent applications. Oftentimes there will
- 24 be hundreds of references cited.
- The present pending legislation would fix that

what it's going to cost you to defend yourself against it, so

there is a real cost to having invalid patents out there in

3 that if someone is actually asserting them and they bother to

file litigation, then you have to go ahead and deal with that.

It would be wonderful if we had an effective
reexamination process that provided you with an alternative
to having litigated against these patents, and I think some
of the solutions that Nancy's mentioned would go a long way
in getting us there, but I'm still not sure that it's enough,

and there's a number of reasons for that.

11

12

13

14

15

16

17

18

19

20

2.1

2.2

23

24

25

One is, I don't know that the system even, as proposed, necessarily encourages people who have art to come forward with it, and I'll give you an example. Years ago when we had the pure ex parte system. We instituted a reexamination where we had like nine different references that we felt were all good references against the patent. But we didn't want to come forward with all of them at one time because if you throw them all into it and the Patent Office looks at it and they go ahead and issue the patent over those, over the prior art that you made available, then your chances of ever being able to present any different arguments in litigation related to that prior art pretty much go out the window because you've got a presumption then that the patent office considered that art and decided that the subject matter was patentable anyway.

1	So we filed a reexamination with three of the
2	references. Because it was an inter partes, and we
3	had no right to object to the arguments that were made by the
4	patent owners, we then had to wait until the office issues
5	its response to our first filing. At which point we filed a
6	new reexamination with the next three pieces of art so that
7	we had an opportunity to respond to what was said in the

2.1

2.2

first case.

So that was the system where luckily we had a lot of art and ultimately the patent got knocked out. In fact, we did this three times, but if you only have two references, then you may have to go forward with both of those in order to be able to have what seems like a more fair process.

It's important to recognize why the process isn't necessarily fair because the ownership of the patent, in responding to the reexamination issuance by the patent office, can make a lot of different arguments. Most of the time what they do is go in, slightly modify the patent claims to respond to the reexamination, narrow them -- and it somewhat turns out to be a fairly insignificant way to maybe get around the art -- and they end up with actually stronger claims coming out of the reexamination than they had going into it, because now they've improved how the claims read on technology that other people are utilizing.

They've removed prior art as reference, and as a

- 1 result, they have a patent that's even easier for them to be
- able to litigate, so you don't improve the situation at all.
- 3 You only make it worse. Making it an *inter partes*
- 4 proceeding where the party that's filed it has at least the
- 5 opportunity to argue their case other than the one-time shot
- 6 when they file their reexamination application would be a
- 7 long step in fixing that, as would be the appeal process
- 8 because the practice had been in the past at least to assign
- 9 the same examiner to the question of whether or not to reexamine
- 10 patent.
- Well, the examiner has somewhat of an embedded interest in not having been wrong in the first plembn 8ete

- 1 prior art and come out with a patent that seemingly was more
- 2 valid than it was when it went in, and fortunately the case
- 3 was settled.
- 4 Summary judgment motions were never ruled on, but
- 5 notwithstanding litigation being more expensive than
- 6 reexamination, we were having a lot more faith in the ex
- 7 parte proceeding in the litigation by way of summary
- giudgments motions than we were in reexaminations.
- 9 MR. BARNETT: Nancy?
- 10 MS. LINCK: I wanted to make one comment on what Tim
- 11 said which I think he well stated the ex parte reexam and
- 12 inter partes, if we could have a system that's being
- 13 proposed. On the estoppel issue, if a party is worried about
- estoppel, of course they could always stop at the Board of
- 15 Appeals. If the party felt that if estoppel doesn't kick in
- 16 until that point and a party felt they didn't have a good
- 17 chance before the Federal Circuit based on the record before
- 18 the Patent and Trademark Office, they could stop at that
- 19 point and estoppel would not be an issue.
- 20 MR. BARNETT: Richard?
- 21 MR. STALLMAN: The phenomenon of a patent becoming
- 22 more dangerous after reexamination is something I've been
- worried about too, and it calls to mind a phenomenon I've seen
- that as the context of activity changes, then what you have
- is that basically the same idea would take a different form

- 1 question like many of the others I've asked. I'm wondering,
- 2 if you change to having a reexamination where both parties
- 3 are present, would that in and of itself reduce the danger
- 4 that the patent holder would simply rewrite the claims to
- 5 stand up and gerrymander the claims, basically, or would you
- 6 need other changes in the system to prevent that?
- 7 MR. CASEY: That's why I'm proposing that you would
- 8 need additional changes because right now, they have the
- 9 ability to go in and amend the claims here in the process in
- order to defend any argument presented.
- MS. LINCK: You have to have a basis in the
- specification so if it's something that's newly developed
- like the web based server that you were speaking of, they
- couldn't just add that to the claims unless it's supported by
- 15 the specification written ten years earlier.
- MR. STALLMAN: We're miscommunicating. I am imaging
- 17 a patent issued in the 1990s, when there already were web
- 18 based applications and that would have covered both, and the
- 19 scenario is that the defendants dig up prior art which
- 20 involves a client server application prior art from the
- 21 1980s, not that it's a patent from the 1980s.
- 22 MR. CASEY: Just to address that issue, I think it's
- an open question as to whether or not you can do that. The
- 24 Federal Circuit just came out with a new case, Johnson &

- disclosed it in the specification but you didn't write claims
- to cover it, you're now going to be barred from being able to
- 3 go back and reclaim the material that was disclosed.
- I'm not quite sure whether it's even a great result.
- 5 MS. LINCK: That's a doctrine of equivalents case.
- 6 MR. CASEY: Right, you're not going to be able to
- 7 argue through the doctrine of equivalents that you have a
- 8 right to that material, but would you be able to go back? And
- 9 they said in part of it that your solution is to go and seek
- 10 a reissue of the patented claim material that you hadn't
- 11 previously claimed. But if that's barred by doctrine of
- equivalents, then there's got to be some question as to
- whether or not it's really appropriate to go back and claim
- stuff through the reissue process when people out in the
- 15 public thought it was part of the disclosed material in the
- 16 first place.
- 17 So you're still going to have a lot of uncertainty
- 18 related to what someone can cover in the specification long
- 19 after the fact.
- MR. BARNETT: Nancy?
- 21 MS. LINCK: As far as going back and recapturing the
- 22 material by reissue, you certainly cannot broaden your claims
- after two years in any way that would capture something that
- would not have been captured under the broader claims, so I
- 25 think that's part of --

- 1 MR. CASEY: Right, but you can narrow it any time.
- MS. LINCK: You can narrow the claims, yes.
- 3 MR. CASEY: It doesn't take a lot to narrow the
- 4 claim. It may be one word.
- 5 MS. LINCK: If you narrow claims, then the original
- 6 alleged infringer was already ensnared by the original --

1 server type implementation, they could then narrow their claim

- 2 to gerrymander it around that prior art, so it's not a matter of
- 3 broadening in any sense of the word.
- 4 It's a matter of making it immune, basically
- 5 withdrawing from whatever little islands the actual prior art
- 6 happens to be in, so that they can defend everything else. And
- 7 because of the constant change in surrounding
- 8 technological context, you can just be sure that what people
- 9 actually want to do today is different from what they
- 10 actually wanted to do in the 1980s, which means that
- 11 narrowing to withdraw from the specific prior art of the
- 12 1980s is always possible while still having what people want
- 13 to do today.
- 14 Always is an exaggeration -- very, very often. Once in
- awhile there's a living fossil.
- MR. BARNETT: Dean?
- 17 MR. ALDERUCCI: I merely want to make sure I
- 18 understand -- for my own edification I want to understand
- 19 your example -- so are you saying that the claims that would
- 20 cover both web and client server embodiments, that was a
- 21 valid claim, and it was supported by the original
- 22 specification that was filed in the '90s or it's invalid?
- 23 MR. STALLMAN: I'll not sure which sense of valid. It's
- invalid because you then find prior art from the 1980s, so in
- 25 that sense if looked at on its own without the possibility of

- 1 narrowing it would be invalid.
- 2 MR. ALDERUCCI: But the portion of it as it were --
- 3 not that you can have partially valid and partially invalid
- 4 claims, but the portion of it that was web based was not in
- 5 the prior art, is that part of the example?
- 6 MR. STALLMAN: Well, if you believe that that's
- 7 really a separate idea, if your threshold for what
- 8 constitutes an invention is that low that just using a web
- 9 based communication technique instead of a specially written
- 10 client server program would really make an invention, indeed
- 11 by that low standard the web based one would be an
- 12 invention.
- Now, I don't think that's true. I think that's a
- foolish way to look at it, but as long as the patent system
- looks at it that way, you will have this phenomenon that by
- 16 narrowing the claim to just the particular details of the way
- 17 people would do it that would be most useful to do it in
- 18 today's context, they can get a valid claim emerging to
- 19 replace the invalid one.
- 20 MR. ALDERUCCI: I see. The claim was directed to --
- one embodiment was clearly invalid because it was not new and
- 22 because it was obvious.
- MR. STALLMAN: I would say it should be obvious from
- 24 the previous one, but in fact the way the patent system seems
- to judge the issue of obviousness, their threshold is very,

1 very low. You have a phenomenon where prior art becomes like

- 2 American soldiers in Vietnam. They cover the ground that
- 3 they stand on, but they don't project their force to any
- 4 distance because the distance to which they project their
- 5 force is measured by the threshold of unobviousness when that
- 6 is very low. Essentially whatever examples you find from the
- 7 past make no difference at all.
- 8 MR. BARNETT: We night step back a moment, and one
- 9 thing I'm interested in, in lieu of a reexam system, I guess
- when in doubt, litigation is the only other option. I'm
- interested to ask, Les, we've heard testimony at least in the
- semiconductor industry and you had mentioned earlier this
- notion of an escalating number and more and more people are
- patenting and conceivably that leads to cross licensing
- 15 situations, but I'm curious if you can let us know sort of
- 16 the math that goes on, or compare and contrast litigation
- decisions when you're dealing with a competitor or participant
- in the market who has a patent in litigation versus a patent
- 19 holder who is not a participant in the market?
- 20 I'm curious if there's a difference there or if you
- 21 have any thoughts on that. Could you pass the microphone
- 22 over to Les, please?
- MR. HART: First of all, in my experience, probably if
- you're trying to license your patents, I would say 80 percent of
- 25 the time you're going to come to an amicable resolution of this

- with the party that you're negotiating with.
- 2 So we're dealing with the other 20 percent where your
- 3 choices are about three or about two. You can forget it; go
- 4 away mad, but go away; or exercise the only other option you
- 5 have and that is to go into court. Of those 20 percent, in
- 6 my experience, probably 80 percent of the 20 percent settle
- 7 very quickly after the litigation has started.
- It might start some discovery, but in the cases I have
- 9 seen, very few cases seem to go through trial, verdict and
- 10 judgment.
- So for the vast majority of the cases of semiconductor
- 12 cross licenses negotiated as part of the settlement, you get
- a far better result because a judgment in a patent litigation
- only is dealing with past damages. And whether or not you're
- going to get an injunction going forward or settling the
- 16 whole thing on the cross license basis covers the future,
- 17 covers both sides' patents.
- 18 It covers the issues of the patents you're going to
- 19 get on inventions in the next period of the term, which
- 20 typically in our industry has been five years. So settling
- 21 these things is a lot better than litigating, but when you do
- litigation, the settlement is a lot better than what you
- would get with a judgment because it's far more all
- 24 inclusive.
- MR. BARNETT: I might ask a follow-up. I guess in

- some of the prior testimony, we heard concern that with the
- 2 increasing frequency of patenting in the semiconductor industry,
- 3 there is a situation with a lot more patent holders who aren't
- 4 interested in cross licensing and are more, for lack of a better
- 5 term, strictly rent seeking, and if you noticed, is that an
- 6 increasing trend and if so, what your thoughts were?
- 7 MR. HART: Yes. Just give me a little more
- 8 clarification. It was not clear to me exactly what you're
- 9 getting at. Rent seekers are new entrants in to the field
- 10 that do not have a patent position?
- MR. BARNETT: Rent seekers being someone who does
- have a patent but who is not a participant or not an entrant
- 13 into
- the market and so they're not interested necessarily in a those license and more sr32b a

1 to license them, and the money we got from that, we invested

- in the R&D that we otherwise couldn't afford to do in the
- 3 business line that we wanted to be in.
- 4 MR. BARNETT: Tim?
- MR. CASEY: Going back to one thing that we haven't
- 6 addressed, and it seems to relate to this, arguably patents have
- 7 caused this to happen in the marketplace in the first place, and
- 8 in the context of licensing, if you at least start with the
- 9 premise that patents exist at least in certain industries -- I'm
- 10 not going to get into that argument -- and will continue to
- 11 exist in those industries for some period of time, and the
- unlikelihood that we're simply going to get rid of them, then
- 13 you have a couple of scenarios that you can follow.
- One is when someone asserts a patent against you,
- what do you do? Well, you can hope it goes away. Sometimes
- 16 that works. You can seek to license it, either through a
- 17 cross license or through the payment of money or through the
- 18 trading of services. I think that factor gets underlooked
- 19 a lot, that everyone assumes that every patent asserted
- results in someone having to pay money for it and that's
- 21 often not the case. They trade things. I've traded all sorts
- of things in patent license agreements that weren't money per
- se, but that enabled the company that I was working with to
- enter into a market that it wasn't in, to develop those product
- lines that it didn't have, all by virtue of being able to

1 utilize the patents as leverage. That enabled us to be able to

- get someone to pay attention to us who may not have otherwise
- 3 wanted to do so.
- And in some cases, where the opposing party is someone
- 5 who has a large portfolio of patents, you can get a freedom to
- 6 operate. And that gets underlooked in terms of the value that
- 7 that brings forward in many cases because a lot of companies,
- 8 because of the existence of these patents, spend a lot of time
- 9 and a lot of resources trying to avoid infringing on somebody
- 10 else's patented technology.
- And many times that time and resource is wasted
- 12 effort that could be better spent if they had a license to
- the patents that that company has and no longer had to worry
- about whether or not they were infringing and could in fact
- 15 actively seek to utilize them. In a number of cases where
- we've entered into patent licenses that ended up costing us much
- 17 less than we ever thought that they would, when we analyzed it
- from a damage perspective -- what's the potential risk we have
- 19 here? -- and we found we were able to get a license for pennies
- on the dollar, compared to what we thought the risk was, that we
- 21 then had the freedom to be able to utilize the patented
- technology.
- 23 And we would go through, look at the portfolio, and
- figure out what groups in the company might be able to make
- use of it. We make those patents available to them and say,

1 "Use this stuff, go through here and see anything you want,

- and you're now free to utilize it, " and that's actually had
- 3 some very positive benefits in terms of the product changes
- 4 and innovations that the company has been able to come
- forward as a result of that.
- The other thing is, patents will also prompt people to
- 7 seek a way around them, and I think that's very important to
- 8 remember as one -- what I always thought, whether or not it
- 9 really was is hard to say -- motive behind the patent
- 10 system in the first place.
- If someone has a patent on something, you can either
- pay them for it, stop using it or find a way around it, and
- perhaps the most significant way in which patents promote
- innovation is the fact that sometimes they force people to find
- a way around it. Well, how do they find around it? They have
- 16 to invent something else. They have to come up with something
- 17 new that enables them to avoid that.
- It may be a very small change, but in other cases it
- may be something that's quite significant. So you have to look
- 20 at that aspect of what are patents adding and I think that's
- 21 fairly substantially significant.
- 22 MR. BARNETT: Les and then Richard? .
- MR. HART: On the notion of designing around patents,
- there's an added danger in doing that versus paying what it
- takes to get a license. And that is, if you're going to design

- 1 around, you better do it well because if you are in
- litigation and you don't have a good legal opinion that the
- 3 course you did take did avoid the patent or if you don't have a
- 4 good legal opinion that says you don't need a license, as you
- 5 all know, you're faced with the prospect of being unlawfully
- 6 infringing.
- 7 And I bet in cases like that, there's an in-house
- 8 counsel during the course of the year, you can get -- I'm
- 9 sure Tim knows this too -- you can get a very large number of
- 10 charges of infringement from people that are out there. I
- just think of college professors being one of the more
- typical examples where you'll get a letter saying, "This
- patent we think you're using and the business you're in, you
- 14 get a lot of them. To send every one of those out to an
- 15 outside counsel to get an opinion that you're not infringing
- 16 a valid claim can be very, very expensive.
- 17 So you rely on in-house counsel to do a preliminary
- 18 check to see whether or not you have a problem or not. And
- again, if you're in litigation, you're relying on in-house
- counsel's opinion that you've done it well enough to avoid
- 21 a unlawful infringement.
- 22 So there's a root example of why you may be very well
- off just taking a license and getting the free use, or
- thereafter the incremental free use, of all of these patents
- 25 rather than just trying to avoid it and run that risk of

1 I think they should have that freedom. I would like to have

1 compression algorithm instead of LZW for their images. That's

- 2 not the only example. There's an Apple patent covering font
- 3 hinting in true type fonts.
- 4 Now, we might be able to come up with another way of
- 5 doing font hinting, but it would do us no good, so the result
- is in our community we can't have good looking fonts. To
- 7 redevelop all those fonts would be a gigantic job.
- 8 Little by little that may be what we have to do, but
- 9 simply developing a better technique to do the job that this
- 10 patent covers a way of doing wouldn't help us at all. You have
- 11 to look at the effects of patents in the structure of the feed
- to see what they're really doing.
- 13 If Microsoft has patents on aspects of .NET, then
- first of all we might find a better way of doing it, but if
- 15 that isn't 100 percent compatible with the applications users
- 16 write for .NET, it won't do us any good at all. It might
- 17 be technologically superior. Hell, there might be things that
- we already know that are technologically superior that everybody
- 19 knows aren't patented. It still won't do any good at providing
- 20 users a practical alternative to Microsoft.
- 21 MR. BARNETT: Thanks, Richard. At this point I think
- we're getting close in time.
- I might open the floor for any closing comments, but
- one I think I am interested in in the context of that and
- 25 perhaps combine them or whatnot, is we talked a lot about the

- 1 impacts of patents on innovation, and I'm curious if anyone
- 2 has any thoughts on sort of the flipside of that, how
- 3 competition affects innovation.
- 4 MR. ALDERUCCI: I'll comment that Richard apparently
- 5 has standards which are technologically inferior, but are still
- 6 entrenched in the industry, and it's not because of their patent
- 7 position that it's so entrenched. It's presumably because of
- 8 their market position. Is that true?
- 9 MR. STALLMAN: Well, yes, that's true. They get it
- 10 entrenched. They can make it. They can entrench it because
- of their market position, and then they use the patents to
- 12 prevent us from doing any effective competition to it.
- 13 MS. MUSACCHIA: I want to add something on the LZW
- 14 because I think one of the things with compression algorithms
- is that there's a huge debate in the software field about
- that particular patent. I always find it very interesting
- 17 that Richard is citing it because there are a number of
- 18 companies and literature about compression algorithms.
- And so some people have argued, and you can read it
- 20 in the literature -- have argued that the LZW patent and
- 21 compression actually snuck up on somebody because they were
- off using compression algorithms that they had themselves
- created, but because of the way it was written and drawn it
- 24 was also a somewhat not broad.
- 25 And I'm out of my depth of field a little bit, but

there were people that were concerned about whether or not

2 they did or did not infringe such a patent because you could

3 go into the literature and find from innumerable places

4 discussion in actual formula on a compression algorithm.

2.2

2.4

And so that is one of those cases where there was quite a bit of debate and probably still remains so. The other issue, in terms of Richard's comment, that people didn't move for some societal reason, a lot of times compression algorithms are very, very deep in product so it's not merely a matter of saying we're trying to persuade somebody to change. A lot of times it's very difficult to make a change once something is already embedded in a piece of technology, embedded deep in a product, so this is something else to be recognized.

On a closing comment basis, the only thing I wanted to say is that again going back to the position that we have been advocating about Europe, and I very much appreciate Dean's comment, the European system is one where while the EPO will go ahead and grant the patents, the cases that the gentleman may have been referencing were possible interpretations by the various countries because the enforcement is done by the individual nations within the European Union.

The European Union, though, has within the last six months come in order and said in their push within the union

1 itself to get more harmonization and bring all the countries

- 2 in line so some of the judicial interpretations where you may
- 3 have found an individual country or court in a country coming in
- 4 one direction or going in another, if you read some of the
- 5 public statements, and there's been articles in the Wall Street
- 6 Journal recently on this very point.
- 7 The Europeans take it on the chin from the U.S.
- 8 companies as they come to us and complain about the fact that
- 9 we are going to have stricter standards. And that is the
- direction that at least the European Union Commission is
- 11 talking about pushing when they harmonize even in their
- judicial settings within the European union.
- 13 Again I appreciate very much when you have cases
- where you're going to find courts in some of the countries
- 15 going in different directions but that's not where the actual
- 16 union is going.
- 17 And so the last point I wanted to make is my
- summary comment. This is an industry where there are a large
- 19 number of small significant inventors. I'm on the Board of
- 20 Directors in NCEITA, North Carolina Electric and Information
- 21 Technology Association. They did a study in North Carolina --
- just call NCEITA, they'll give it to you -- and they found in
- North Carolina we have in excess, I think, of 4,000 small high
- tech companies in the information technology field of which
- less than 10 percent have more than 15 employees.

- Well, when you begin to think about it, that means
 there are an awful lot of companies out there that are coming
 out of the University of North Carolina in Charlotte, people
 that are being spun off out of University of North Carolina
 at NC State, NC state campuses.
- These companies are small, and yet they're 6 They are the ones that are creating a lot of new 7 innovative. 8 technology. So I would recommend anybody, again if you want 9 to see where some of the small companies are, look at the local trade associations that exist within those states and 10 11 start asking them how many members do they have? How many of those companies are small? What are their sizes? And then ask 12 13 what their business is? How many of them are developing 14 technology in the security field? How many of them are 15 developing technology of one type or another? And I think you 16 will find a lot of interesting information. They're not going to be litigating. They may not even be patenting 17 because they can't afford it. 18

They can't get the attorneys' opinions because they don't have the money. They're still looking for angel funds and VC funding, the idea of finding the money to do the other, but this is where that innovative heart is coming from.

And again as you look at it, please go out in the field to some of these small technology trade associations

19

20

21

2.2

2.3

- and see who is out there and what they're actually doing as
- 2 opposed to what some of the larger people who can afford to
- 3 send me up here for a couple days are doing.
- 4 Thank you.
- 5 MR. BARNETT: Tim?
- 6 MR. CASEY: It's an interesting thought. The patents
- 7 are a form of competition in and amongst themselves. We
- 8 often look at patents in terms of how it's affecting
- 9 competition in other areas, but clearly just based on what
- 10 you've heard today, there's any of a number of people out
- there who are competing solely on the basis of patents, and
- that is the competition, and in fact that is the industry.
- So sometimes I think we view patents in the context of
- 14 the industries in which they are around, but they are a form of
- 15 competition amongst people in industries or in technology much
- the same way as companies compete for employees or capital or
- 17 customers or any of a number of other things.
- And in terms of barriers of entry into that
- 19 particular field, a barrier of entry into being able to compete
- 20 in the patent field is significantly less than it is in many
- other areas. In fact an inventor can write their own patent
- 22 application.
- The patent office provides directions and will help
- 24 pro se applicants in trying to put together a patent
- application without utilizing an attorney, although it's not

- 1 necessarily always the greatest idea. Especially if you
- think you have something that's very valuable, you might want
- 3 to get some professional help, but there is the ability to be
- 4 able to do that.
- 5 The price is relatively low if you go about it that
- 6 way. But even if you use an attorney, your fees may range
- 7 from \$10,000 to \$30,000 to get an application on file and
- 8 prosecute it through the patent office, which is significantly
- 9 less than the billions of dollars that it might cost you to
- 10 build your own semiconductor fab, so certainly the barrier to
- 11 entry in that market is quite a bit different.
- 12 And in fact, there's nothing stopping anybody from
- patenting anything that they may develop and entering the
- 14 market whenever they want to. You may not be able to build
- the market, but you can certainly build things having to do
- 16 with semiconductors and have a patent on it and actually have
- 17 a say in the marketplace as a result of that that you may not
- 18 otherwise have as an individual.
- 19 MR. BARNETT: Thanks, Tim.
- 20 Richard?
- 21 MR. STALLMAN: I don't know whether to cry or laugh
- 22 at the idea that people can compete using patents. It's
- true, of course, once you have patents you'll get people
- competing just to get patents, and they will have a say in
- the marketplace and a negative kind of say, so I can't

dispute any of the facts that you've just said. Whether this

- is a good thing for society, though, is a different question.
- Now, it may not matter so much with regard to making
- 4 semiconductors. You say it costs a large amount of money to
- 5 set up a fab line, and those that have that enough money can
- afford to deal with the patent system. For them it's a side
- 7 issue.
- But for a lot of us, free software developers don't
- 9 spend ten thousand dollars and if we had to, it would be
- 10 crippling. That's the thing that gives free software its
- 11 strength. It doesn't take any labor, just their labor.
- 12 That's what makes it possible for us to develop a spectrum of
- software that covers the whole range of things people want to
- do and do it so well.
- 15 So we are in danger of being crushed. If it costs as
- 16 much to develop a software package as it does to build a fab
- 17 line, the situation would be very different.
- 18 MR. BARNETT: Thanks, Richard.
- 19 Nancy?
- 20 MS. LINCK: In the drug industry we have essentially
- 21 two kinds of competitors. We have other proprietary drug
- 22 companies, and then we have the generic drug companies. And
- with respect to the proprietary drug companies, we try very
- hard to develop our drugs so that they don't fall within the
- 25 claims of another competitor. But in fact, if we have strong

- 1 patent protection for our drug, developing a drug to cure a
- disease is such a difficult process that our primary focus is
- 3 moving that drug forward, and we will find a way to market
- 4 that drug.
- I don't know of any drugs that have been developed
- 6 that would treat diseases that have been kept off the market
- by a competitor's patents. Maybe that's because I've only
- 8 been in the drug business for three and a half years, but I
- 9 think drug companies work together to make sure that drugs that
- 10 can help people get on the market.
- 11 With respect to generic drug companies, they are
- 12 growing rapidly and taking over more and more of the
- pharmaceutical sector, and I believe the average life of a
- patent once you get approval for a drug is about 11
- 15 years, not the full term of the patent.
- 16 So we try very hard during the drug development
- 17 process to get follow-on, I believe you call them sequential
- or follow-on patents to the formulations or to the dosages or
- 19 to different indications, in an attempt to get more of our

once youhejesperatikeretend infrestochtuigesistilmeretinen ütdire zahenses valteritejeogritizeesabbrug valevieltapen 211

- 1 according to a Tufts survey, so that's how we deal with
- 2 competition.
- 3 Thank you.
- 4 MR. BARNETT: We'll finish with Les.
- 5 MR. HART: Regarding patents and competition
- 6 between big companies and small companies, the small company
- 7 that would get a patent on its innovations early on has a
- \$ tremendous amount of leverage against large companies later
- 9 on, if that high gear becomes part of the mainstream of
- 10 technology.

1	CERTIFICATION OF REPORTER
2	
3	CASE TITLE: COMPETITION AND INTELLECTUAL PROPERTY LAW AND
4	POLICY IN THE KNOWLEDGE-BASED ECONOMY
5	HEARING DATE: APRIL 9, 2002
6	
7	I HEREBY CERTIFY that the transcript contained herein
8	is a full and accurate transcript of the notes taken by me at
9	the hearing on the above cause before the FEDERAL TRADE
10	COMMISSION to the best of my knowledge and belief.
11	
12	DATED: APRIL 16, 2002
13	
14	
15	DEBRA L. MAHEUX
16	
17	CERTIFICATION OF PROOFREADER